Literature DB >> 3145097

Basic characteristics of noradrenaline release in the hippocampus of intact and 6-hydroxydopamine-lesioned rats as studied by in vivo microdialysis.

P Kalén1, M Kokaia, O Lindvall, A Björklund.   

Abstract

Extracellular levels of noradrenaline (NA) were measured in the hippocampus of awake and halothane-anaesthetized rats, using intracerebral dialysis coupled to a highly sensitive radioenzymatic assay. In awake animals, steady state NA output after 1 h of perfusion was 69 +/- 21 fmol/30 microliter (15 min). Non-noxious sensory stimulation increased the steady state NA output by 35%, while halothane anaesthesia reduced the levels by 63-72%. During halothane anaesthesia KCl (100 mM) or desipramine (5 microM) added to the perfusion medium increased the NA levels 27-fold and 8-fold, respectively. Tetrodotoxin added in the presence of desipramine reduced the extracellular NA levels by 85%. In 6-OHDA lesioned animals the NA levels were below the limit of detection in virtually all samples (i.e. less than 3 fmol/30 microliter) at 10-16 days after lesion, but there was a partial recovery at longer postoperative time points. These results support the conclusion that the extracellular NA levels recovered in the dialysis perfusates are neuronally derived and can be used as an index of noradrenergic synaptic activity in the brain.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3145097     DOI: 10.1016/0006-8993(88)90454-4

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Electrical stimulation of the lateral habenula increases hippocampal noradrenaline release as monitored by in vivo microdialysis.

Authors:  P Kalén; O Lindvall; A Björklund
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

Review 2.  Methodological considerations in rat brain BOLD contrast pharmacological MRI.

Authors:  C A Steward; C A Marsden; M J W Prior; P G Morris; Y B Shah
Journal:  Psychopharmacology (Berl)       Date:  2005-09-14       Impact factor: 4.530

3.  Extracellular brain cortical levels of noradrenaline in ischemia: effects of desipramine and postischemic administration of idazoxan.

Authors:  I Gustafson; E J Westerberg; T Wieloch
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

4.  Acute effects of L-tryptophan on brain extracellular 5-HT and 5-HIAA levels in chronic experimental portal-systemic encephalopathy.

Authors:  P B Bergqvist; S Hjorth; G Apelqvist; F Bengtsson
Journal:  Metab Brain Dis       Date:  1996-09       Impact factor: 3.584

5.  Release of norepinephrine in the preoptic area activates anteroventral periventricular nucleus neurons and stimulates the surge of luteinizing hormone.

Authors:  Raphael E Szawka; Maristela O Poletini; Cristiane M Leite; Marcelo P Bernuci; Bruna Kalil; Leonardo B D Mendonça; Ruither O G Carolino; Cleyde V V Helena; Richard Bertram; Celso R Franci; Janete A Anselmo-Franci
Journal:  Endocrinology       Date:  2012-11-13       Impact factor: 4.736

6.  Noradrenergic hyperactivity in hippocampus after partial denervation: pharmacological, behavioral, and electrophysiological studies.

Authors:  C Dyon-Laurent; A Hervé; S J Sara
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

7.  Evidence that 5-HT2 receptor activation decreases noradrenaline release in rat hippocampus in vivo.

Authors:  C J Done; T Sharp
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  Seizure suppression in kindling epilepsy by intracerebral implants of GABA- but not by noradrenaline-releasing polymer matrices.

Authors:  M Kokaia; P Aebischer; E Elmér; J Bengzon; P Kalén; Z Kokaia; O Lindvall
Journal:  Exp Brain Res       Date:  1994       Impact factor: 1.972

Review 9.  Potential role of cerebral cytochrome P450 in clinical pharmacokinetics: modulation by endogenous compounds.

Authors:  Guillermo Gervasini; Juan Antonio Carrillo; Julio Benitez
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.